TERAZOSIN

Fetal Risk Summary

Terazosin is a peripherally acting a1-adrenergic blocking agent used in the treatment of hypertension and symptomatic benign prostatic hyperplasia.

Reproduction studies in rats and rabbits at doses 280 and 60 times the recommended maximum human dose (RMHD) revealed no teratogenic effects, but an increased incidence of fetal resorptions occurred in both species (1). In addition, decreased fetal weight and an increased number of supernumerary ribs were observed in rabbit offspring. The embryo/fetal toxicity in both species was attributed to maternal toxicity (1). A significant increase in rat pup mortality was also seen at doses more than 75 times the RMHD in peri- and postnatal studies (1).

No reports describing the use of terazosin in human pregnancy have been located.

Breast Feeding Summary

No reports describing the use of terazosin during lactation have been located. The molecular weight (about 460 for the hydrochloride salt) is low enough, however, that excretion into breast milk should be expected.

Reference